- Parties: The plaintiffs were AstraZeneca Canada Inc. and Kudos Pharmaceuticals Limited. The defendant was Natco Pharma (Canada) Inc. 

- Subject Matter: This Federal Court action under the Patented Medicines Regulations (PMDR) involves a patent infringement claim by AstraZeneca Canada Inc. and Kudos Pharmaceuticals Limited against Natco Pharma (Canada) Inc. regarding the "400 Patent," which relates to pharmaceutical formulations containing olaparib (marketed as Lynparza) in a solid dispersion with a matrix polymer exhibiting low hygroscopicity and high softening temperature. Natco denies infringement, asserting that its product does not fall within the scope of the Asserted Claims, and counterclaims that the patent is invalid on grounds of obviousness, insufficiency/ambiguity, overbreadth, and lack of sound prediction/utility. The case is ongoing.

- Date: The hearing was set on March 27, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.